Dexrazoxane
Based on 19 publication(s) in Google Scholar
Dexrazoxane, as an intracellular iron chelating agent, reduces the formation of superoxide radicals and has cardioprotective, anti-inflammatory, antioxidant, anti-tumor and neuroprotective activities. Dexrazoxane inhibits ferroptosis of H9c2 cells by inhibiting HMGB1. Dexrazoxane induces DNA damage and apoptosis in human fibrosarcoma cells .
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.88%
- CAS No.: 24584-09-6
- Formule: C11H16N4O4
- Masse moléculaire:268.27
-
Stockage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
CNS-Penetrant Compound Library
HY-L028
-
Drug Repurposing Compound Library
HY-L035
-
Antioxidant Compound Library
HY-L037
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Ferroptosis Compound Library
HY-L051
-
NMPA-Approved Drug Library
HY-L053
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Neuroprotective Compound Library
HY-L070
-
Transcription Factor-Targeted Library
HY-L090
-
Rare Diseases Drug Library
HY-L102
-
Pediatric Drug Library
HY-L104
-
Chemotherapy Drug Library
HY-L112
-
EMA-Approved Drug Library
HY-L116
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Non-steroidal Anti-Inflammatory Compound Library
HY-L130
-
Withdrawn Drug Compound Library
HY-L140
-
Off-patent Drug Library
HY-L141
-
Cell Death Library
HY-L162
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
Anti-Fibrosis Compound Library
HY-L185
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Lactylation Compound Library
HY-L249
Publications Citing Use of MedChemExpress (MCE) Dexrazoxane
More- Nat Med. 2016 May;22(5):547-56. [Abstract]
- Adv Sci (Weinh). 2023 May;10(15):e2206007. [Abstract]
- Nano Res. 2023 Apr 18.
- J Pharm Anal. 2026 Mar 10.
- Phytomedicine. 2025 Oct 3:148:157357. [Abstract]
- Phytomedicine. 2025 Nov:147:157220. [Abstract]
- Phytomedicine. 2023 Aug:117:154922. [Abstract]
- Free Radic Biol Med. 2024 Dec 9:227:296-311. [Abstract]
- Free Radic Biol Med. 2020 Nov 20;160:303-318. [Abstract]
- Br J Pharmacol. 2025 Jun;182(11):2409-2425. [Abstract]
- Biomed Pharmacother. 2022 Sep:153:113280. [Abstract]
- Eur J Med Chem. 2024 Nov 26:283:117108. [Abstract]
- Biochem Pharmacol. 2024 Jun:224:116247. [Abstract]
- J Ethnopharmacol. 2025 Oct 14:120751. [Abstract]
- J Cell Mol Med. 2025 Jun;29(11):e70641. [Abstract]
- Environ Toxicol Pharmacol. 2023 Oct:103:104261. [Abstract]
- Cardiovasc Toxicol. 2024 Aug;24(8):818-835. [Abstract]
- Mol Med Rep. 2024 May;29(5):84. [Abstract]
- Biochem Biophys Res Commun. 2025 Sep 8:778:152417. [Abstract]
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
Flow Cytometry
-
Cell Imaging/Staining
-
RT-PCR
-
In Vivo Efficacy Study
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HL-60 | IC50 |
18 μM
Compound: DEX; ICRF-187
|
Antiproliferative activity against human HL-60 cells after 72 hrs by XTT assay
Antiproliferative activity against human HL-60 cells after 72 hrs by XTT assay
|
[PMID: 33750129] |
Dexrazoxane (0-500 μM; 0-24 h) induces DNA breaks, ATF3 accumulation, DNA damage response and apoptosis in human fibrosarcoma cell line [4].
Dexrazoxane(100 µM; 72 h) inhibits ferroptosis of H9c2 cells by inhibiting HMGB1[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Topoisomerase IIα-expressing HTETOP cells (HTETOP cells were derived from the human fibrosarcoma cell line HT1080 through the deletion of both endogenous topoisomerase IIα alleles and the insertion of a tetracycline-repressible topoisomerase IIα transgene)
-
Concentration:100 μM
-
Incubation Time:4 h
-
Result:Increased the phosphorylation level of Chk1, Chk2, ATR, and ATM.
-
Cell Line:HTETOP cells
-
Concentration:0, 10,100 and 500 μM
-
Incubation Time:0, 1, 4, 8 and 24 h
-
Result:Increased AFT3 protein levels in a concentration-dependent and incubation time-dependent manner.
-
Cell Line:Topoisomerase IIα-expressing HTETOP cells
-
Concentration:100 μM
-
Incubation Time:24 h
-
Result:Increased the expression level of P53.
-
Cell Line:Doxorubicin (HY-15142) treated H9c2 cells
-
Concentration:100 μM
-
Incubation Time:72 h
-
Result:Decreased the expression level of HMGB1 protein.
Dexrazoxane (5-15 mg/kg; Intraperitoneal injection; 3-5 weeks) has antioxidant and anti-inflammatory effects in rodent models of Parkinson's disease[6].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Doxorubicin (HY-15142) treated Wistar rats aged 11 weeks old[2]
-
Dosage:8 mg/kg
-
Administration:Intravenous injection (i.v.); weekly for 7 weeks
-
Result:Reversed the respiratory or hepatic pathology caused by doxorubicin.
Enhanced cytochrome c-oxidase activity.
Decreased myocardial ROS levels.
Reversed the mitochondrial DNA deletion caused by doxorubicin.
-
Animal Model:6-OHDA (HY-B1081) treated Sprague Dawley rats (180-220 g);
MPTP ( HY-15608 ) and probenecid (HY-B0545) treated mice aged 10 weeks old[6] -
Dosage:5 and 15 mg/kg;
10 mg/kg -
Administration:Intraperitoneal injection (i.p.); 3 weeks
Intraperitoneal injection (i.p.); 5 weeks -
Result:Attenuated neurotoxin-induced oxidative damage in serum, midbrain and striatum.
Suppressed neurotoxin-induced systemic inflammation in both of serum and midbrain.
Ameliorated neurotoxin-induced ER stress in midbrain.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 24584-09-6
-
Appearance Solid
-
Masse moléculaire 268.27
-
Formule C11H16N4O4
-
Color White to light yellow
-
SMILES
C[C@H](N(C1)CC(NC1=O)=O)CN(C2)CC(NC2=O)=O
-
Synonyms
ICRF-187; ADR-529; NSC-169780
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (19)
-
Journal Impact Factor
-
Most Recent
-
Nat Med
Human induced pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of breast cancer patients to doxorubicin-induced cardiotoxicity. [Abstract]2016 May;22(5):547-56. PMID: 27089514 -
Adv Sci (Weinh)
The Imbalance of p53-Park7 Signaling Axis Induces Iron Homeostasis Dysfunction in Doxorubicin-Challenged Cardiomyocytes. [Abstract]2023 May;10(15):e2206007. PMID: 36967569
Dexrazoxane purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 May;10(15):e2206007. [Abstract]
Dexrazoxane (DXZ) (1 µM; 24 h) resulted in a decline in contractile speed in NMCMs.
Dexrazoxane purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 May;10(15):e2206007. [Abstract]
Dexrazoxane (DXZ) (1 µM; 24 h) resulted in a decline in cell viability in NMCMs.
Dexrazoxane purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 May;10(15):e2206007. [Abstract]
Dexrazoxane (DXZ) (1 µM; 24 h) inhibited DOX-induced iron accumulation and ROS and restored mitochondrial membrane potential in NMCMs.
Dexrazoxane purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 May;10(15):e2206007. [Abstract]
Dexrazoxane (DXZ) (1 µM; 24 h) reversed Ptgs2 mRNA expression in NMCMs.
Dexrazoxane purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2023 May;10(15):e2206007. [Abstract]
Dexrazoxane (DXZ) (20 mg/kg; i.p.; weekly for 4 weeks) reversed the DOX-induced decrease in body weight and the ratio of heart weight to tibia length (HW/TL) of chronic DoIC (doxorubicin (DOX)-induced cardiotoxicity) mice.
-
-
-
Phytomedicine
Quercetin ameliorates doxorubicin-induced atrial fibrillation via EGFR-mediated restoration of autophagic flux. [Abstract]2025 Oct 3:148:157357. PMID: 41056856 -
Phytomedicine
20-Deoxyingenol attenuated doxorubicin-induced cardiotoxicity by promoting autolysosome degradation through the UCHL3-TFEB pathway. [Abstract]2025 Nov:147:157220. PMID: 40916238 -
Phytomedicine
Amentoflavone mitigates doxorubicin-induced cardiotoxicity by suppressing cardiomyocyte pyroptosis and inflammation through inhibition of the STING/NLRP3 signalling pathway. [Abstract]2023 Aug:117:154922. PMID: 37321078 -
Free Radic Biol Med
2024 Dec 9:227:296-311. PMID: 39653130 -
Free Radic Biol Med
2020 Nov 20;160:303-318. PMID: 32846217 -
Br J Pharmacol
Targeting FDX1 by trilobatin to inhibit cuproptosis in doxorubicin-induced cardiotoxicity. [Abstract]2025 Jun;182(11):2409-2425. PMID: 39933533 -
Biomed Pharmacother
2022 Sep:153:113280. PMID: 35724508 -
Eur J Med Chem
Praeruptorin A screened by a ferrous ion probe inhibited DMT1 and ferroptosis to attenuate Doxorubicin-induced cardiomyopathy. [Abstract]2024 Nov 26:283:117108. PMID: 39615370 -
Biochem Pharmacol
Calcium saccharate/DUSP6 suppresses renal cell carcinoma glycolytic metabolism and boosts sunitinib efficacy via the ERK-AKT pathway. [Abstract]2024 Jun:224:116247. PMID: 38697311 -
J Ethnopharmacol
Huanglian-ejiao decoction ameliorates doxorubicin-induced cardiomyocyte apoptosis and autophagic flux dysregulation by up-regulating ubiquilin1. [Abstract]2025 Oct 14:120751. PMID: 41101550 -
J Cell Mol Med
Downregulation of Alox5 Inhibits Ferroptosis to Improve Doxorubicin-Induced Cardiotoxicity via the P53/SLC7A11 Pathway. [Abstract]2025 Jun;29(11):e70641. PMID: 40485049 -
Environ Toxicol Pharmacol
Poly (ADP-ribose) polymerase pathway inhibitor (Olaparib) upregulates SERCA2a expression and attenuates doxorubicin-induced cardiomyopathy in mice. [Abstract]2023 Oct:103:104261. PMID: 37689219 -
Cardiovasc Toxicol
Marein Alleviates Doxorubicin-Induced Cardiotoxicity through FAK/AKT Pathway Modulation while Potentiating its Anticancer Activity. [Abstract]2024 Aug;24(8):818-835. PMID: 38896162 -
Mol Med Rep
Food therapy of scutellarein ameliorates pirarubicin‑induced cardiotoxicity in rats by inhibiting apoptosis and ferroptosis through regulation of NOX2‑induced oxidative stress. [Abstract]2024 May;29(5):84. PMID: 38516760 -
Biochem Biophys Res Commun
The m6A modification reader protein IGF2BP2 regulates ferroptosis in nasopharyngeal carcinoma cells by stabilizing CP expression via an m6A-dependent mechanism. [Abstract]2025 Sep 8:778:152417. PMID: 40743989
Solvant et solubilité
DMSO : 25 mg/mL (93.19 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (9.32 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.32 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 15% Cremophor EL 85% Saline
Solubility: 6.67 mg/mL (24.86 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (282 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Rahimi P, et al. Efficacy of Dexrazoxane in Cardiac Protection in Pediatric Patients Treated With Anthracyclines. Cureus. 2023 Apr 8;15(4):e37308. [Content Brief]
[2]. Lebrecht D, et al. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br J Pharmacol. 2007 Jul;151(6):771-8. [Content Brief]
[3]. de Baat EC, et al. Primary cardioprotection with dexrazoxane in patients with childhood cancer who are expected to receive anthracyclines: recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Child Adolesc Health. 2022 Dec;6(12):885-894. [Content Brief]
[4]. Deng S, et al. The catalytic topoisomerase II inhibitor dexrazoxane induces DNA breaks, ATF3 and the DNA damage response in cancer cells. Br J Pharmacol. 2015 May;172(9):2246-57. [Content Brief]
[5]. Zhang H, et al. Protective Effects of Dexazoxane on Rat Ferroptosis in Doxorubicin-Induced Cardiomyopathy Through Regulating HMGB1. Front Cardiovasc Med. 2021 Jul 14;8:685434. doi: 10.3389/fcvm.2021.685434. [Content Brief]
[6]. Mei M, et al. Antioxidant and anti-inflammatory effects of dexrazoxane on dopaminergic neuron degeneration in rodent models of Parkinson's disease. Neuropharmacology. 2019 Dec 1;160:107758. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.7276 mL | 18.6379 mL | 37.2759 mL | 93.1897 mL |
| 5 mM | 0.7455 mL | 3.7276 mL | 7.4552 mL | 18.6379 mL | |
| 10 mM | 0.3728 mL | 1.8638 mL | 3.7276 mL | 9.3190 mL | |
| 15 mM | 0.2485 mL | 1.2425 mL | 2.4851 mL | 6.2126 mL | |
| 20 mM | 0.1864 mL | 0.9319 mL | 1.8638 mL | 4.6595 mL | |
| 25 mM | 0.1491 mL | 0.7455 mL | 1.4910 mL | 3.7276 mL | |
| 30 mM | 0.1243 mL | 0.6213 mL | 1.2425 mL | 3.1063 mL | |
| 40 mM | 0.0932 mL | 0.4659 mL | 0.9319 mL | 2.3297 mL | |
| 50 mM | 0.0746 mL | 0.3728 mL | 0.7455 mL | 1.8638 mL | |
| 60 mM | 0.0621 mL | 0.3106 mL | 0.6213 mL | 1.5532 mL | |
| 80 mM | 0.0466 mL | 0.2330 mL | 0.4659 mL | 1.1649 mL |
Powered by Bioz